Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Planning Underway for Phase 3 Development of Tezepelumab in COPD   THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m.

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Agios Pharmaceuticals

Ocular Therapeutix

Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities.

The 3 Best Biotech Stocks to Buy Now: Q2 Edition

Canadian Solar

Diana Shipping

Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade high. Achieving this outcome consistently would be ideal.

3 Stocks to Buy Low Today With High Hopes for Tomorrow

Amgen has a history of outperforming peers and the market due to its effective capital allocation in the pharmaceutical industry. AMGN is executing well with sales and volume growth, and has a robust development pipeline. Biosimilars growth is accelerating and AMGN currently offers value at the current price along with a respectable and well-covered dividend yield.

Amgen: I Prefer To Chase Value And Dividends

Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024, focusing on expanding sales of rare disease drugs and advancing drugs in oncology. Despite strong financial results in FY'23, Amgen's valuation is dependent on future growth and managing its significant debt.

Amgen: The Giant With An Impressive Pipeline

In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.

Amgen (AMGN) Laps the Stock Market: Here's Why

Ascendis Pharma

Cytokinetics

DexCom

Edwards Lifesciences

Tema Obesity & Cardiometabolic ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

Eli Lilly

Medtronic

Novo Nordisk

SPDR S&P 500 ETF Trust

Viking Therapeutics

Vertex Pharmaceuticals

Health Care Select Sector SPDR Fund

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

It's been a volatile start to the second quarter for many sectors. However, investors continue to seek out undervalued biotech stocks for robust returns over the long term.

3 High-Growth Biotech Stocks Investors Shouldn't Sleep On in April

Home Depot

Merck

Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden's efforts to steer the economy through inflation concerns are showing strong results.

The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024

Sarepta Therapeutics

Amgen's lineup and pipeline should help its financial results and keep its dividend intact. While lesser known, Sarepta is proving itself to be a highly innovative biotech company.

2 Biotech Stocks to Buy Hand Over Fist in April

Amgen (AMGN) concluded the recent trading session at $269.95, signifying a +0.69% move from its prior day's close.

Amgen (AMGN) Ascends But Remains Behind Market: Some Facts to Note

NextEra Energy

Realty Income Corp

PepsiCo

As the retirement crisis looms, urgent action is key. The financial industry's failure to address rising retirement costs exacerbates the situation. Investing in dividend-growth stocks emerges as a crucial strategy. Realty Income, NextEra Energy, PepsiCo, and Amgen offer stability and growth, with consistent income streams and strong balance sheets. These stocks present investors with not only reliable income but also promising long-term potential, bolstered by their sound financial standing.

Building A $1.4 Million Retirement Fund: 4 Stocks Yielding Up To 6% To Get The Job Done

AbbVie

As we look forward to celebrating World Health Day on April 7th, these are the top three healthcare US companies we think you should be watching for your financial health.  1. Lilly (Eli) & Co.

Top three US healthcare stocks to buy in April

Amgen AMGN is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health, nephrology and neuroscience markets.

Here's Why Amgen (AMGN) Stock is Outperforming the Industry

Apple

Amazon

Boeing

Cisco Systems

Chevron

Disney

Dow Inc

Goldman Sachs

Johnson & Johnson

Coca-Cola

McDonald's

Microsoft

NIKE

UnitedHealth Group

Verizon

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.”–Dow Jones & Co. The highest-yield 10 stocks are April's Dogs of the Dow: GS, JNJ, KO, AMGN, CSCO, IBM, CVX, DOW, MMM, and VZ. They only averaged a 3.97% annual yield, as prices. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated April net gains ranged from 11.38%-26.62%, topped by BA 3/28/24.

April Dogs Of The Dow: Buy 1, Watch 4

Gilead Sciences

The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.

Biotech Sector Nears Breakout: Will it Outperform in Q2?

Amgen (AMGN) closed the most recent trading day at $283.04, moving -0.45% from the previous trading session.

Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again

Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity candidate MariTide and other promising treatments in its pipeline, could potentially surpass Eli Lilly in the obesity market. Amgen's stock is undervalued compared to Eli Lilly, offers a dividend yield of 3.2%, and has the potential for significant growth if its obesity treatments are successful.

Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock

Altimmune

Madrigal Pharmaceuticals

Rhythm Pharmaceuticals

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are answering the urgent need for effective solutions with a new generation of weight loss drugs capable of achieving previously unattainable levels of weight reduction.

7 Stocks That Will Drive the Weight Loss Drugs Market

Pyxis Oncology

SPDR S&P Biotech ETF

One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.

3 Biotech Stocks to Buy on the Dip: March 2024

Honeywell

Intel

The Dow Jones Industrial Average recently made new all-time highs, reaching a peak of 39,889. This has set off great excitement, with 40,000 seeming imminent and the possibility of Dow 50,000 starting to take shape.

7 Dow Stocks to Buy on the Dip: March 2024

Exelon

Pfizer

Warren Buffett stocks can teach you a thing or two about investing. Warren Buffett's annual shareholders letter to Berkshire Hathaway (NYSE: BRK-A )(NYSE: BRK-B ) investors outlines what he's done the past year and often why.

Buffett's Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating

Salesforce

Dow Jones 40,000 is a milestone investors have eyed for years. But now a handful of stocks are posed to make it a reality.

Dow 40,000 Is Coming Any Day Now Thanks To 8 Stocks, Analysts Say

News for Amgen Stock (AMGN)